Denosumab

British Journal of Clinical Pharmacology

Volumn 71, Issue 6, 2011, Pages 804-806

  Dubois, Eline A ^a   Rissmann, Robert ^a,b   Cohen, Adam F ^a,b  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CENTRE FOR HUMAN DRUG RESEARCH   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

DENOSUMAB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN G2; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; TUMOR NECROSIS FACTOR;

CATARACT; CELL INTERACTION; HUMAN; HYPOCALCEMIA; NOTE; OSTEOBLAST; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; PROSTATE CANCER; RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ANTIBODIES, MONOCLONAL; BONE REMODELING; FEMALE; HUMANS; MALE; OSTEOCLASTS; OSTEOPOROSIS; RANK LIGAND;

EID: 79955854103     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2011.03969.x     Document Type: Note

References (4)

1. European Public Assessment Report. Available at (last accessed 4 April 2011).
2. Rizzoli R, Yasothan U, Kirkpatrick P. Fresh from the Pipeline: denosumab. Nat Rev Drug Discov 2010; 9: 591-2.
3. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C, FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009; 361: 756-65.
4. ClinicalTrials.gov Identifier: NCT00925600. Available at .